SecBot SecBot
8-K ·Filed Apr 8, 2026

REGN

REGENERON PHARMACEUTICALS, INC.
NEUTRAL
Impact 4/10
Horizonweeks Processed7mo ago SEC0001104659-26-040661
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor the company's final Q1 2026 earnings release for confirmation of this IPR&D charge and any additional details on the underlying transactions. The charge is non-recurring but could signal new strategic partnerships or acquisitions.

DirectionNeutral
Confidencemedium
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$775.36
T+0 close · Apr 8, 2026 · via day close
Latest settled
−15.62%
T+60 · $654.27
Vs SPY
−25.79%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 8 $775.36entry
  2. T+1 · 7mo ago −1.34%α −1.91% · $764.98
  3. T+5 · 7mo ago −3.06%α −6.58% · $751.63
  4. T+20 · 7mo ago −9.43%α −17.97% · $702.27
  5. T+60 · 4mo ago −15.62%α −25.79% · $654.27
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Regeneron Pharmaceuticals expects a $102 million acquired in-process R&D charge in Q1 2026, which will reduce both GAAP and non-GAAP net income per diluted share by approximately $0.81. This is a preliminary estimate ahead of final financial statement closing.

Key Facts

  • Regeneron expects a $102 million acquired in-process research and development (IPR&D) charge in Q1 2026
  • The charge primarily relates to premiums on equity securities purchased, development milestones, and up-front payments from collaboration and licensing agreements
  • The IPR&D charge is expected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.81
  • The company notes that actual results may differ from these preliminary estimates as financial statements are not yet finalized

Financial Impact

Approximately $102 million pre-tax charge, reducing EPS by $0.81

net incomeeps

Risk Factors

  • Actual results may differ from these preliminary estimates
  • The IPR&D charge reflects non-cash expenses that could impact investor perception of profitability

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
79% bullish (38 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-040661
Document: 0001104659-26-040661-index-headers.html0001104659-26-040661
Document: 0001104659-26-040661-index.html0001104659-26-040661
Document: 0001104659-26-040661.txt0001104659-26-040661
8-K Data (Synthetic)0001104659-26-040661

Track record

53 reports on REGN

Performance horizon

11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
  2. Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
  3. Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
  4. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  5. Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
  6. Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  7. Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
  8. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
  10. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
Showing 10 of 53

US Market Status

Market Closed · Opens Wed (10h 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026